Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization
ConditionPCI
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University
About this trial
The study investigates the role of Lipoprotein(a) \[Lp(a)\] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Disqualifiers
Acute coronary syndrome within 30 days
Trial design
Treatments tested in this trial
- Not listed
Trial groups
156 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov